계명대학교 의학도서관 Repository

Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study

Metadata Downloads
Author(s)
Shin, JinhoChoi, Yu JeongHong, Geu-RuJeon, Dong WoonKim, Dae-HyeokKoh, Young YoupMancia, GiuseppeManolis, Athanasios J.Yoon, Hyuck-JunPark, Sang Won
Keimyung Author(s)
Yoon, Hyuck Jun
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Hypertension
Issued Date
2020
Volume
38
Issue
3
Keyword
add-on therapyAsiancombination therapyessential hypertensionmonotherapynebivolol
Abstract
Objective:
The efficacy and safety of nebivolol in patients with hypertension is well established, but its effect in Asian patients with essential hypertension in the real world has not been studied.

Methods:
Adult South Korean patients with essential hypertension, with or without comorbidities, were enrolled to participate in this prospective, single-arm, open, observational study; 3011 patients received nebivolol either as monotherapy or add-on therapy. Changes in SBP, DBP and heart rate (HR) at 12 and 24 weeks were evaluated. Subgroup analysis for BP changes in newly diagnosed (de novo) patients and those receiving other antihypertensives at study entry were also conducted.

Results:
Nebivolol significantly decreased mean SBP and DBP at 12 and 24 weeks compared with baseline (P < 0.0001). A significant reduction in HR was also observed at 12 and 24 weeks (P < 0.0001). The reductions of SBP and DBP were notably greater when nebivolol was used as monotherapy in de novo patients (P < 0.0001) and as add-on therapy to existing antihypertensives (angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors and calcium channel blockers; P < 0.0001). Majority of the reported adverse events were mild; the most common adverse events were dizziness (1.3%), headache (1.0%) and dyspnea (0.9%).

Conclusion:
Despite the limitations associated with observational studies, this real-world study in Asian patients with essential hypertension with and without comorbidities, demonstrated the efficacy and safety of once daily nebivolol, either as monotherapy or add-on therapy.
Keimyung Author(s)(Kor)
윤혁준
Publisher
School of Medicine (의과대학)
Citation
Shin, Jinho et al. (2020). Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study. Journal of Hypertension, 38(3), 527–535. doi: 10.1097/HJH.0000000000002296
Type
Article
ISSN
1473-5598
Source
https://journals.lww.com/jhypertension/Fulltext/2020/03000/Real_world_efficacy_and_safety_of_nebivolol_in.23.aspx
DOI
10.1097/HJH.0000000000002296
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43168
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.